Home > What we do > Medicine & Healthcare > hMedicine > hMedicine Story

Placental Cells Mitigate Radiation-Induced Complications in Mice, Hadassah Researchers Reveal

Placental cells, Hadassah Medical Organization researchers have shown, were successful in mitigating acute radiation-induced complications in mice when transplantation was initiated 24 hours following total body irradiation.

The research team from Hadassah's Biotechnology and Radiobiology Laboratory at the Sharett Institute of Oncology studied two types of placental cells--pure maternal cell preparations (PLX-Mat) and a mixture of maternal ¬and fetal derived cells (PLX-RAD), developed by Pluristem Therapeutics, a leading developer of placenta-based cell therapies. Using intramuscular (IM) injections, they were able to overcome the difficulty experienced by other researchers whereby, with intravenous treatment, the stem cells became trapped mostly in the lungs immediately after administration. Rather, IM injections enabled them to easily deliver higher numbers of cells through multiple injections at different times.

Twenty four hours and five days after total body irradiation, the mice were treated with placental stromal cells (PLX). The researchers discovered that PLX-Mat increased the survival of the irradiation mice from 27 percent to 68 percent, while PLX-RAD cells increased the survival to 98 percent. The researchers found that they could delay the treatment with PLX-RAD up to 48 hours after irradiation with similar success. The study showed that the treated mice regained their weight significantly faster than did the few control survivors. Furthermore, the treatment stimulated extensive hematopoietic (blood producing) stem cell proliferation, which enabled the speedy recovery of the radiation-induced depleted bone marrow with a parallel increase in the number of circulating white blood cells, red blood cells, and platelets.

The Sharett Institute of Oncology is a world leader in cancer research. Its staff is at the cutting edge of treatment of breast and ovarian cancer, melanoma, lung and pancreatic cancer and leukemia.

DONATE

Join

Advocate

Lead

LEARN MORE

View all of our Impact Areas

The authors conclude: "Our study suggests that IM treatment with PLX-RAD cells may serve as a highly effective 'off the shelf' therapy to treat bone marrow failure following total body exposure to high doses of radiation." These cells can be stored, delivered frozen, and then defrosted just before injection.

The researchers add that they expect the treatment may also have major applications for clinical conditions associated with severe bone marrow aplasia, where blood cell development is impaired.

Read more here>>

Date: 6/26/2013

Her Excellency Marie Bashir Sees Bridges to Peace at Hadassah's Hospitals

Hadassah Researcher Honored with Prestigious Prize for Blood Discovery

IVF Babies: A Gift of Israel and Hadassah to Its People

Healing Garden at Hadassah's Hospitals Dedicated to Smorgon Family

International Symposium on Pancreatic Disease Headed Up by Hadassah Specialist

BioLineRx to Commence Phase 1 Stem Cell Trial at Hadassah Medical Organization

Hadassah’s Prof. Eitan Kerem Receives European Cystic Fibrosis Society 2014 Prize

Hadassah's School Awarded 2014 National Education Award

International “No Smoking Day 2014” at Hadassah's Hospitals

Mid-Workout, Hadassah Doctor Sprints to Save a Life

Going Local: Heads of Hadassah’s ERs Forge Bond with Community Pediatricians

Hadassah Doctors Initiate Medical Collaborations in Australia

Hadassah’s Innovative Cardiac Protocol Saves Man’s Life

International Orthopedic Society Invites Hadassah Medical Organization as Member

New Trial Data out of Hadassah Hospitals Show Promise for Stem Cell Treatment of ALS

Oncology Patient Raves About Exceptional Treatment at Hadassah

Ugandan HIV-Positive Orphans Saved by Hadassah Global Outreach

Growing Heart Healthy Kids in the Heart of East Jerusalem

PHOTOS: The Pope Visits Hadassah Hospitals

Prof. Alexander Margulis: Hadassah Pediatric Plastic Surgeon and Israel Navy Seal



More hMedicine Stories




Hadasit, Hadassah’s Technology Transfer Arm, Reviews 2012’s Accomplishments

When the Hadassah University Medical Center’s physicians suggest a solution to a medical problem which can lead to the development of a new medicine or product, Hadasit, Hadassah’s technology transfer arm, explores its feasibility and supports the promotion of those viable ideas with innovation potential. Although 2012 has been “a year full of challenges for the life science industry,” says Einat Zisman, Hadasit’s Chief Executive Officer, Hadasit still signed 125 agreements for clinical trials, all to be done at Hadassah. In addition, Hadasit signed 15 agreements for cooperation and commercialization of technologies that were developed at Hadassah. Click here to read the latest Newsletter from Hadasit >>

   |  Who We Are  |  What We Do  |  Where We Do It  |  Read About It  |  Join Now  |  Donate  |
  |  Login  |  Contact Us  |  Careers  |  Terms & Conditions  |  
Copyright ©2014 Hadassah is a registered trademark of Hadassah, the Women's Zionist Organization of America